司美格鲁肽干预是否调节肥胖女性甜味感知:随机单盲安慰剂对照试验方案
本研究为研究者发起的随机单盲安慰剂对照试验,计划纳入30名肥胖合并多囊卵巢综合征的女性,按1:1随机接受司美格鲁肽1.0 mg或安慰剂治疗16周。主要终点为舌组织转录组表达变化和化学味觉计检测的味觉敏感性变化,次要终点包括fMRI神经反应、体重、脂肪质量及进食行为。
要点
- 首个在临床研究中探讨司美格鲁肽对味觉感知及食物线索神经反应影响的研究方案。
- 纳入肥胖合并PCOS女性,随机1:1接受司美格鲁肽1.0 mg或安慰剂16周。
- 主要终点为舌组织转录组变化和化学味觉计检测的味觉敏感性变化。
核心结论
- 该研究方案旨在探讨司美格鲁肽是否调节肥胖女性的甜味感知及食物线索神经反应。
研究设计与样本
- 研究者发起的随机单盲安慰剂对照临床试验,计划纳入30名肥胖合并多囊卵巢综合征女性。
- 参与者按1:1随机接受司美格鲁肽1.0 mg或安慰剂治疗16周。
主要发现
- 临床研究中GLP-1在味觉感知中的作用尚 largely 未涉及。
- GLP-1受体激动剂的减重效果是否通过调节味觉感知介导目前未知。
关键数值与推荐
- 主要终点为舌组织转录组表达水平从基线至16周随访的变化,通过RNA测序测定。
- 主要终点还包括化学味觉计检测的味觉敏感性变化。
- 次要终点包括fMRI评估的神经反应、体重、脂肪质量及进食行为与食物摄入变化。
临床怎么用
- 研究结果可能将舌和味觉感知确定为GLP-1受体激动剂的新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical studies demonstrated that glucagon-like peptide 1 (GLP-1) is locally synthesized in taste bud cells and that GLP-1 receptor exists on the gustatory nerves in close proximity to GLP-1-containing taste bud cells. This local paracrine GLP-1 signalling seems to be specifically involved in the perception of sweets. However, the role of GLP-1 in taste perception remains largely unaddressed in clinical studies. Whether any weight-reducing effects of GLP-1 receptor agonists are mediated through the modulation of taste perception is currently unknown. METHODS AND ANALYSIS: This is an investigator-initiated, randomized single-blind, placebo-controlled clinical trial. We will enrol 30 women with obesity and polycystic ovary syndrome (PCOS). Participants will be randomized in a 1:1 ratio to either semaglutide 1.0 mg or placebo for 16 weeks. The primary endpoints are alteration of transcriptomic profile of tongue tissue as changes in expression level from baseline to follow-up after 16 weeks of treatment, measured by RNA sequencing, and change in taste sensitivity as detected by chemical gustometry. Secondary endpoints include change in neural response to visual food cues and to sweet-tasting substances as assessed by functional MRI, change in body weight, change in fat mass and change in eating behaviour and food intake. DISCUSSION: This is the first study to investigate the role of semaglutide on taste perception, along with a neural response to visual food cues in reward processing regions. The study may identify the tongue and the taste perception as a novel target for GLP-1 receptor agonists. ETHICS AND DISSEMINATIONS: The study has been approved by the Slovene National Medical Ethics Committee and will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Results will be submitted for publication in an international peer-reviewed scientific journal. TRIAL REGISTRATION: ClinicalTrials.gov NCT04263415 . Retrospectively registered on 10 February 2020.
引用
- Jensterle M, Ferjan S, Battelino T, et al. Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial. Trials. 2021. PMID: 34281590. doi:10.1186/s13063-021-05442-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。